(Q36036704)

11 August 2017

1 reference

title

Gene therapy progress and prospects: novel gene therapy approaches for AIDS. (English)

1 reference

11 August 2017

0 references

Wolkowicz R

1

1 reference

11 August 2017

Nolan GP

series ordinal

2

1 reference

11 August 2017

language of work or name

1 reference

1 March 2005

1 reference

11 August 2017

1 reference

11 August 2017

12

1 reference

11 August 2017

6

1 reference

11 August 2017

467-476

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.gt.3302488

11 August 2017

0 references

cites work

Lentiviral and MLV based retroviral vectors for ex vivo and in vivo gene transfer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

Transduction efficiency of MLV but not of HIV-1 vectors is pseudotype dependent on human primary T lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

Efficient lentiviral vectors for short hairpin RNA delivery into human cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

Gene therapy of HIV-1 infection using lentiviral vectors expressing anti-HIV-1 genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

Lentiviral vectors: turning a deadly foe into a therapeutic agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

Lentiviruses in gene therapy clinical research

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

Lentiviral vector-mediated gene transfer in T cells from Wiskott-Aldrich syndrome patients leads to functional correction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

Efficient marking of murine long-term repopulating stem cells targeting unseparated marrow cells at low lentiviral vector particle concentration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

A novel lentivirus vector derived from apathogenic simian immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

Efficient transduction of pancreatic islets by feline immunodeficiency virus vectors1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

FIV: from lentivirus to lentivector

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

Novel interfering bifunctional molecules against the CCR5 coreceptor are efficient inhibitors of HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

Reduced cell surface expression of CCR5 in CCR5Delta 32 heterozygotes is mediated by gene dosage, rather than by receptor sequestration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

The multimerization of human immunodeficiency virus type I Vif protein: a requirement for Vif function in the viral life cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

Human immunodeficiency virus type 1 Vpr-mediated G(2) cell cycle arrest: Vpr interferes with cell cycle signaling cascades by interacting with the B subunit of serine/threonine protein phosphatase 2A

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

HIV-1 VPR modulates cell cycle G2/M transition through an alternative cellular mechanism other than the classic mitotic checkpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

Transdominant activity of human immunodeficiency virus type 1 Vpr with a mutation at residue R73.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

Inhibition of HIV-1 virion production by a transdominant mutant of integrase interactor 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

HIV-1 proprotein processing as a target for gene therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

Inhibiting AIDS in the central nervous system: gene delivery to protect neurons from HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

Functional neutralization of HIV-1 Vif protein by intracellular immunization inhibits reverse transcription and viral replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

Inhibition of HIV-1 replication in primary human T cells transduced with an intracellular anti-HIV-1 p17 antibody gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

Recombinant human antibodies against the reverse transcriptase of human immunodeficiency virus type-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

Inhibition of HIV-1 infection by down-regulation of the CXCR4 co-receptor using an intracellular single chain variable fragment against CXCR4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

Inhibition of Tat-mediated transactivation and HIV-1 replication by human anti-hCyclinT1 intrabodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

Repression of the HIV-1 5' LTR promoter and inhibition of HIV-1 replication by using engineered zinc-finger transcription factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

Attenuation of HIV-1 replication in primary human cells with a designed zinc finger transcription factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

RelA-associated inhibitor blocks transcription of human immunodeficiency virus type 1 by inhibiting NF-kappaB and Sp1 actions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

RNA-mediated inhibition of HIV in a gene therapy setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

HIV-1 TAR as anchoring site for optimized catalytic RNAs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

Development and testing of retroviral vectors expressing multimeric hammerhead ribozymes targeted against all major clades of HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

Modulation of HIV-1 replication by RNA interference

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

Localized expression of small RNA inhibitors in human cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

Cloned zebrafish by nuclear transfer from long-term-cultured cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

Potent and specific inhibition of human immunodeficiency virus type 1 replication by RNA interference

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

Human immunodeficiency virus type 1 escape from RNA interference

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

Inhibition of human immunodeficiency virus type 1 replication by RNA interference directed against human transcription elongation factor P-TEFb (CDK9/CyclinT1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

Incorporation of lysyl-tRNA synthetase into human immunodeficiency virus type 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

Specific inhibition of the synthesis of human lysyl-tRNA synthetase results in decreases in tRNA(Lys) incorporation, tRNA(3)(Lys) annealing to viral RNA, and viral infectivity in human immunodeficiency virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

Potent suppression of HIV type 1 infection by a short hairpin anti-CXCR4 siRNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

Specific HIV-1 env gene silencing by small interfering RNAs in human peripheral blood mononuclear cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

Inhibition of human immunodeficiency virus type 1 replication in primary macrophages by using Tat- or CCR5-specific small interfering RNAs expressed from a lentivirus vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

Inhibition of HIV-1 infection by lentiviral vectors expressing Pol III-promoted anti-HIV RNAs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

Mechanisms of viral membrane fusion and its inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

Toxicity of antiretroviral therapy and implications for drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

Inhibiting HIV-1 entry with fusion inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

Membrane-anchored peptide inhibits human immunodeficiency virus entry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

Inhibition of human immunodeficiency virus type 1 entry in cells expressing gp41-derived peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

Emergence of a drug-dependent human immunodeficiency virus type 1 variant during therapy with the T20 fusion inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

The efficiency of simian foamy virus vector type-1 (SFV-1) in nondividing cells and in human PBLs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

Resistance is futile: assimilation of cellular machinery by HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

Overexpression of the N-terminal domain of TSG101 inhibits HIV-1 budding by blocking late domain function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

Role of ESCRT-I in retroviral budding

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

The Protein Network of HIV Budding

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

AIP1/ALIX Is a Binding Partner for HIV-1 p6 and EIAV p9 Functioning in Virus Budding

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

Cell-type-dependent targeting of human immunodeficiency virus type 1 assembly to the plasma membrane and the multivesicular body

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

Inhibition of HIV-1 gene expression by novel DNA enzymes targeted to cleave HIV-1 TAR RNA: potential effectiveness against all HIV-1 isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

Anti-HIV inhibitors based on nucleic acids: emergence of aptamers as potent antivirals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

Dominant effector genetics in mammalian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

Retroviral technology--applications for expressed peptide libraries

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

Update on D-ala-peptide T-amide (DAPTA): a viral entry inhibitor that blocks CCR5 chemokine receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

Human immunodeficiency virus type 1 Vif binds the viral protease by interaction with its N-terminal region

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

Abrogation of Vif function by peptide derived from the N-terminal region of the human immunodeficiency virus type 1 (HIV-1) protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

HIV: replication trimmed back.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

HIV-1 Vif Blocks the Antiviral Activity of APOBEC3G by Impairing Both Its Translation and Intracellular Stability

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

Influence of primate lentiviral Vif and proteasome inhibitors on human immunodeficiency virus type 1 virion packaging of APOBEC3G.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

The prion protein has DNA strand transfer properties similar to retroviral nucleocapsid protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

Analysis of the interactions between HIV-1 and the cellular prion protein in a human cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

The gene product Murr1 restricts HIV-1 replication in resting CD4+ lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

Heat shock protein 70 protects cells from cell cycle arrest and apoptosis induced by human immunodeficiency virus type 1 viral protein R

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

Heat-shock protein 70 exerts opposing effects on Vpr-dependent and Vpr-independent HIV-1 replication in macrophages.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

Control of HIV-1 infection by soluble factors of the immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

Contribution of human alpha-defensin 1, 2, and 3 to the anti-HIV-1 activity of CD8 antiviral factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

Retraction of an Interpretation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

CAF-mediated human immunodeficiency virus (HIV) type 1 transcriptional inhibition is distinct from alpha-defensin-1 HIV inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

The CD8+ cell noncytotoxic anti-HIV response can be blocked by protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

Ribonuclease is partly responsible for the HIV-1 inhibitory effect activated by HLA alloantigen recognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

HIV and AIDS: looking ahead

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

HIV and AIDS in relation to other pandemics. Among the viruses plaguing humans, HIV is a recent acquisition. Its outstanding success as an infection poses immense scientific challenges to human health and raises the question "What comes nest?".

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

WHO puts HIV/AIDS pandemic at top of its agenda

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

Genetic therapy for HIV/AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

Anchoring hairpin ribozymes to long target RNAs by loop-loop RNA interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

inferred from DOI database lookup

7 January 2021

based on heuristic

Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

inferred from DOI database lookup

7 January 2021

based on heuristic

How resting T cells deMURR HIV infection

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302488

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/SJ.GT.3302488

1 reference

Dimensions Publication ID

11 August 2017

0 references

1 reference